Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Eribulin|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: NSABP Foundation Inc
Collaborators: Eisai Inc.